Holen Sie sich die Stockscreener-App
169.80
3.48%
5.71
Schlusskurs vom Vortag:
$164.09
Offen:
$163.07
24-Stunden-Volumen:
1.74M
Relative Volume:
2.03
Marktkapitalisierung:
$4.25B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-18.52
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-8.92%
1M Leistung:
-10.64%
6M Leistung:
+350.64%
1J Leistung:
+132.41%
1-Tages-Spanne:
$160.11
$174.06
1-Wochen-Bereich:
$160.11
$198.43
52-Wochen-Spanne:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
169.80 | 4.10B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines Stock (PRAX) Opinions on Short Report Controversy - Quiver Quantitative
Praxis Precision Medicines general counsel sells $4.8m in shares - Investing.com
Praxis Precision Medicines exec sells $2.6m in shares - Investing.com
Praxis Precision Medicines exec sells $2.6m in shares By Investing.com - Investing.com India
Is Praxis Precision Medicines Inc. stock near bottom after declineJuly 2025 Price Swings & Reliable Momentum Entry Alerts - newser.com
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) to Discuss Ulixacaltamide Data on Nov. 24 Call - Stock Titan
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' - Benzinga
Praxis Precision Medicines (PRAX) Faces Challenges as Culper Res - GuruFocus
Praxis Precision Medicines drops after Culper Research short call (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines stock falls after Culper short report By Investing.com - Investing.com Canada
Culper Research says we are short Praxis Precision Medicines Inc - MarketScreener
Is Praxis Precision Medicines Inc. stock supported by strong fundamentalsWeekly Profit Report & Fast Gain Stock Tips - newser.com
How analysts rate Praxis Precision Medicines Inc. stock todayTrend Reversal & Accurate Intraday Trade Tips - newser.com
Praxis a new buy at BTIG as biotech is a top pick for 2026 - Seeking Alpha
Is Praxis Precision Medicines Inc. stock a contrarian buyWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
BTIG Research Initiates Coverage on Praxis Precision Medicines With Buy Rating, $424 Price Target - MarketScreener
BTIG Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Using fundamentals and technicals on Praxis Precision Medicines Inc.July 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
BTIG Initiates Coverage on PRAX with Buy Rating and $424 Price T - GuruFocus
Published on: 2025-11-19 03:37:53 - newser.com
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Quarterly Investment Review & Daily Stock Trend Reports - newser.com
Commit To Purchase Praxis Precision Medicines At $100, Earn 27.5% Using Options - Nasdaq
Praxis Precision Medicines (PRAX) Price Target Increased by 11.27% to 287.79 - Nasdaq
What valuation multiples suggest for Praxis Precision Medicines Inc. stockIPO Watch & Entry Point Strategy Guides - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025. - MarketScreener
How institutional buying supports Praxis Precision Medicines Inc. stockPortfolio Update Summary & AI Powered Trade Plan Recommendations - newser.com
Published on: 2025-11-15 06:25:23 - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesMarket Growth Summary & Weekly Setup with High ROI Potential - newser.com
PRAX: HC Wainwright & Co. Raises Price Target to $258 | PRAX Sto - GuruFocus
Published on: 2025-11-12 17:26:58 - newser.com
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):